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OBJECTIVES The aim of this study was to determine whether the extent of viability or scar is important in
the amount of recovery of left ventricular (LV) function, and to develop a model for
predicting recovery after revascularization that could be tested in a randomized trial.
BACKGROUND F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) is used to define
viable myocardium in patients with coronary artery disease (CAD) and severe LV dysfunction
and to guide revascularization decisions. Whether this approach improves clinical outcomes
has not been tested in a randomized trial. Before doing so, an objective model for prediction
of recovery is required.
METHODS A total of 82 patients with CAD and an ejection fraction (EF) 35% had FDG PET perfusion
imaging before revascularization. Complete follow-up was available on 70 patients (86%). Patients
had radionuclide angiograms at baseline and three months post-revascularization.
RESULTS Diabetes (p  0.029), time to operation (p  0.008), and scar score (p  0.001) were
significant independent predictors of the change in EF. Previous coronary artery bypass graft
confounded the effect of age. There was a significant interaction between the perfusion tracer
used and mismatch score (p  0.02). The multivariable prediction model incorporating PET
and clinical variables had a goodness of fit with p  0.001. Across tertiles of scar scores (I,
small: 0% to 16%; II, moderate: 16% to 27.5%; III, large: 27.5% to 47%), the changes in EFs
were 9.0  1.9%, 3.7  1.6%, and 1.3  1.5% (p  0.003: I vs. III), respectively.
CONCLUSIONS In patients with severe LV dysfunction, the amount of scar was a significant independent
predictor of LV function recovery after revascularization. A combination of PET and clinical
parameters predicts the degree of recovery. This model is being applied in a large randomized
controlled trial to determine the effectiveness of therapy guided by FDG PET. (J Am Coll
Cardiol 2002;40:1735–43) © 2002 by the American College of Cardiology Foundation
Patients with ischemic heart disease and severe left ventric-
ular (LV) dysfunction have high morbidity and mortality
(1–4). Such patients may have hibernating viable myocar-
dium, but are at significant risk for cardiac events if they do
not undergo timely revascularization (2,5–7). In patients
with severe LV dysfunction, F-18-fluorodeoxyglucose
(FDG) imaging is considered by many to be the best means
for defining viability (4,8–12) and has proven useful in
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predicting regional and global recovery of LV function
following revascularization (4,6,10,13–18). However, there
is only limited understanding of the extent and severity of
FDG abnormalities that are required to predict degrees of
improvement in LV function following revascularization
(14,19). This represents a key unresolved issue in viability
imaging (18).
Retrospective and cohort studies suggest that the use of
From the *Cardiac PET Centre, Divisions of Cardiology and Cardiac Surgery,
University of Ottawa Heart Institute, Ottawa, Ontario, Canada; †Divisions of Cardi-
ology and Cardiac Surgery, Toronto Hospital Western and General Divisions and St.
Michael’s Hospital, University of Toronto Health Sciences Network, Toronto,
Ontario, Canada; ‡E. S. Garnett Memorial PET Centre, Department of Radiology,
McMaster University and Department of Nuclear Medicine, Hamilton Health
Sciences, Hamilton, Ontario, Canada; §Divisions of Cardiology and Cardiac Surgery,
McMaster University, Hamilton, Ontario, Canada; Division of Cardiology, London
Health Sciences Centre, London, Ontario, Canada; and the ¶Cardiovascular Out-
comes Related to Economics Group, Department of Epidemiology and Community
Medicine, University of Ottawa, Ottawa, Ontario, Canada. The study was supported
in part by the Heart and Stroke Foundation of Ontario (HSFO grant # NA-4316 and
T-3570). Dr. Beanlands is a Research Scientist supported by the Canadian Institutes
for Health Research. Dr. Nichol is a Career Scientist supported by the Ontario
Ministry of Health. Dr. Burns passed away during the course of the study.
Manuscript received February 15, 2002; revised manuscript received May 24, 2002,
accepted June 24, 2002.
Journal of the American College of Cardiology Vol. 40, No. 10, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)02489-0
FDG positron emission tomography (PET) imaging may
have impact on patient outcome (2,5,7,20). However, there
are no large prospective randomized controlled trials that
focus on patients with severe LV dysfunction, the group of
patients where FDG PET may have the greatest benefit.
Recent data have shown that FDG PET imaging can
impact clinical decision making (6,20–25). However, the
integration of both viability and clinical parameters may be
helpful in optimizing therapy decisions for patients with
severe LV dysfunction. Before undertaking a randomized
controlled trial of FDG PET on patient outcome, it is
necessary to understand what degree of viability will predict
what level of LV function recovery, and how integration
with other clinical parameters will affect the prediction of
recovery.
The aim of this study was to determine whether the
extent of viable or scarred myocardium is important in the
level of recovery of LV function among patients with severe
coronary disease and severe LV dysfunction, and to develop
a model that incorporates viability and clinical parameters
for predicting the degree of recovery after revascularization
that could be tested in a similar patient population in a
prospective randomized controlled trial.
METHODS
Patient population and study design. This was a prospec-
tive multicenter cohort study. Included were patients with
coronary artery disease (CAD) and severe LV dysfunction
with an ejection fraction (EF) 35% by any quantitative
technique, who were being scheduled for revascularization.
Excluded were those patients with myocardial infarction
within the preceding six weeks, severe valve disease requir-
ing valve replacement, requirement for aneurysm resection,
and inability to obtain informed consent. Patients had
evaluation of myocardial viability at the Cardiac PET
Centre of the University of Ottawa Heart Institute (64
patients enrolled from eastern Ontario, northern Ontario,
and western Quebec) or the E. S. Garnett Memorial PET
Centre of McMaster University (18 patients enrolled from
southwestern Ontario at McMaster University Medical
Centre, University of Toronto Health Sciences Network,
and London Health Sciences Centre).
After providing informed consent, patients underwent
baseline perfusion imaging and FDG PET. Clinical assess-
ment of functional class, radionuclide angiography (RNA),
quality of life questionnaire, and 6-min walk test were done
within two weeks of the FDG PET scan, before revascu-
larization. The RNA was repeated after three months of
follow-up. The absolute change in EF between baseline and
follow-up was then determined.
Evaluation of functional capacity and quality of life. Ca-
nadian Cardiovascular Society angina classification and
New York Heart Association dyspnea classification were
recorded based on patient self-report. The Minnesota Liv-
ing with Heart Failure questionnaire was used to assess
health-related quality of life (26,27). Functional score using
this approach ranges from 0 (good) to 105 (poor). Submaxi-
mal exercise capacity was determined using the 6-min walk
test as a safe and objective means for evaluating the
functional status of patients (28,29).
RNA. TheRNAswereacquiredusingastandardelectrocardio-
gram-gated equilibrium blood pool imaging protocol, using
Tc-99m-labelled red blood cells (6,13–15,17,22). The EF was
measured from the left anterior oblique 45° acquisition. The
RNA analysis was performed in a central core laboratory by
observers (R.M. Iwanochko and R. J. Burns, Toronto
Hospital) who were blind to any clinical or imaging data
(30,31).
FDG PET. A standardized protocol for static FDG PET
imaging was used. Patients without diabetes were studied in
the postprandial state after a 50-g oral glucose load. Those
patients with diabetes or glucose intolerance also received
insulin according to a standardized protocol (2,4–6,14,15,
22,32,33).
Initial PET transmission scanning was performed to
allow for attenuation correction. A 30-min emission scan
was acquired starting 40 min after injection of 75 to 370
MBq of FDG in a whole-body PET camera (CTI/Siemens
ECAT ART, Knoxville, Tennessee). The FDG uptake
images were reconstructed using a Hann window cutoff at
0.2 cycles/pixel.
Perfusion imaging. Where PET perfusion imaging was
available, this was performed using either N-13 ammonia or
rubidium-82. Both of these have been used routinely in
previous studies for perfusion imaging, often interchange-
ably (2,4,5,7,13–15,32,34,35). A dose of 370 to 740 MBq of
rubidium-82 or 300 to 370 MBq of N-13 ammonia was
administered intravenously. Standard perfusion imaging
acquisition protocols were used (32,36–41). Sites without
the capability of PET perfusion imaging performed Tc-99m
sestamibi single photon emission computed tomography
(SPECT) to assess perfusion (4,6,17,22,42). A dose of 740
MBq of Tc-99m sestamibi was administered intravenously,
followed 1 h later by standard 30-min 180° SPECT imaging
protocol. All patients were studied under resting conditions.
The SPECT images were reconstructed with the same
resolution as the PET images and transferred to the PET
computer system for analysis.
Perfusion/FDG image data analysis. The heart was di-
vided into 460 sectors by an automated analysis program
(41,43). For each sector, tracer activity was expressed as a
Abbreviations and Acronyms
CAD  coronary artery disease
EF  ejection fraction
FDG  F-18-fluorodeoxyglucose
LV  left ventricle/ventricular
PET  positron emission tomography
RNA  radionuclide angiogram/angiography
SPECT  single photon emission computed tomography
Tc  technetium
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percentage of the maximum uptake for the patient’s myo-
cardium. The sum of the percentages of all sectors, corrected
for the maximum possible score (maximum score: 46,000 
460 sectors  100%), defined the total “raw perfusion” score
and the total “raw FDG” score, respectively. To normalize
the FDG to perfusion, sectors that were 80% of the
maximum perfusion were defined as normal. FDG uptake
was then normalized by scaling the percent FDG uptake to
be equal to perfusion in the “maximum zone” sectors. After
this normalization, sectors with a value 100% FDG were
assigned a value of 100%. The sums of all sectors were
calculated again to define the total “normalized perfusion”
and the total “normalized FDG” uptake, respectively.
Tissue characterization. In the “abnormal” sectors with
80% perfusion, the extent and severity of hibernating
myocardium (“mismatch” score) and “scar” score could be
defined as a percentage of the total LV myocardium. Thus,
for abnormal sectors:
Scar score 
 100  FDG
46,000
in abnormal sectors  100 	% of LD

In sectors with FDG perfusion, the perfusion score was
substituted for the FDG score in the above equation.
In sectors with FDG  perfusion:
Mismatch score 
 FDG  perfusion
46,000
in abnormal sectors  100 	% of LD

The score parameters consider the combination of extent
and severity. Using this method, sectors with reduced
perfusion can have a mixture of both mismatch and scar
scores. The sum of perfusion, mismatch, and scar scores for
any abnormal sector equals 100%. To evaluate size alone,
the number of sectors defined as scar or mismatch were
considered. Figure 1 shows examples of the polar maps to
determine scar and mismatch scores in three patients.
Statistical analysis. Univariable comparisons evaluated
possible significant associations between potential covariates
and absolute changes in EF, the response variable. Separate
analyses considered relative changes in EF. Size and score
values were considered for the following PET-related vari-
ables: raw FDG, normalized FDG, raw perfusion, normal-
ized perfusion, mismatch score, and scar score. Each of
these variables was modeled as a normal distribution. The
following demographic and clinical variables were consid-
ered: age, gender, baseline EF, previous revascularization,
time to revascularization, symptom class, and diabetes.
Candidate demographic and clinical variables were selected
based on prior evidence of important prognostic factors in
the setting of revascularization (44,45). Although associa-
tions with other variables were plausible, the study had
sample size constraints. Therefore, in addition to obtaining
a satisfactory fit of the data, a secondary goal of the analysis
was to limit the number of variables in the model so that
there would be at least 10 cases per variable in order to avoid
overfitting (44,45).
Multivariable analyses were performed by using stepwise
multiple regression methods. The criterion for possible
inclusion in the multivariable model were univariable p
value 0.2. The criterion for remaining in the multivariable
model was an adjusted p value 0.05. Goodness of fit was
based on assessment of overall model fit and graphic
comparison of observed versus adjusted values residual plots
to identify outlying or influential observations or systematic
patterns (46). To illustrate the association between scar
score and the absolute change in EF on RNA between
baseline and post-revascularization follow-up, the scar score
was compared across tertiles. Interaction terms were con-
sidered. Thus, an indicator variable was included in the
model to account for the potential differences in perfusion
tracer, as the use of PET or SPECT tracers could poten-
tially affect the degree of scar or mismatch defined (8,47,48)
(tracer variable  1 for PET, 0 for SPECT perfusion).
RESULTS
Patient characteristics. Between July 1996 and October
1999, 101 patients were considered for the study. Of these,
two patients (2%) could not complete both tests before the
scheduled revascularization. Thirteen patients (13%) under-
went aneurysm resection, ventricular reconstruction, or
mitral valve replacement and were excluded. Four patients
(4%) had surgery cancelled. Thus, 82 patients (82%) with
baseline FDG PET and RNA met inclusion criteria. Of
these 82 patients, 2 patients (2%) died before follow-up, 1
patient before undergoing surgery and the other patient in
the early postoperative period. One patient had a large
stroke and could not return for follow-up. Six other patients
(7%) were lost to follow-up. Three patients (4%) had
technical difficulties with baseline or follow-up PET or
RNA that could not be analyzed. Thus, 70 patients (85% of
those eligible) had complete follow-up data and were
included in the analysis. The baseline demographic charac-
teristics of these patients are shown in Table 1. There were
51 patients (73%) that had class III to IV dyspnea, whereas
35 patients (50%) had class III to IV angina. The patients’
previous angiography showed that three-vessel CAD and/or
left main coronary artery disease was present in 49 patients
(70%). Every attempt was made to proceed to revascular-
ization as soon as possible after the PET and RNA images.
In 51 patients (71%), revascularization was performed
within six weeks of the FDG PET scan.
Independent predictors of change in LV function. The
following factors were independently and significantly asso-
ciated with absolute change in EF after adjustment for other
factors (Table 2) : scar score (p  0.001), tracer (p  0.043),
time to operation (within 6 weeks) (p  0.008), and
diabetes (p  0.029). The independent effect of the mis-
match score was not significant. After adjustment for a
statistically significant interaction between mismatch and
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perfusion tracer, the net effect of the mismatch score when
using PET perfusion was significant (p  0.085 for mis-
match score, p  0.043 for tracer, p  0.021 for the
interaction term). Because of this interaction the net effect
of mismatch is better understood by considering the fitted
values (discussed in the following text and in Table 3). Prior
coronary artery bypass graft was included in the model
because it confounded the estimate for age.
Multivariable correlates of change in LV function. Al-
though multivariable models of absolute and relative
changes in EF were similar, a better goodness of fit was
achieved with absolute change in EF. Therefore, adjusted
values were calculated for absolute change in EF (Table 3).
The overall fit of the model was significant (F  4.35, df 
8, p  0.001). No observations were identified as being
outlying or influential. Table 3 describes the overall effect of
an incremental change in selected variables on the fitted
Figure 1. Examples of reconstructed polar maps for three patients: A, B, C. In each set, the top panel is the raw perfusion (left) and raw
F-18-fluorodeoxyglucose (FDG) uptake (right) polar maps; middle panel is the normalized perfusion and FDG uptake; and the lowest panel is the scar
score (left) and mismatch score (right). (A) Predominantly scar in the inferolateral and anteroseptal walls and apex. Of the total left ventricle (LV)
myocardium, 53% was normal, 42% was scar, and 5% was mismatch. The model predicted a change in ejection fraction (EF) of 0%; observed change was
from 26% to 25%  1%. (B) Partial mismatch (mixture of scar and hibernating myocardium) in the large defect involving the inferolateral wall and apex
extending to the distal anteroseptal wall. Of the total LV myocardium, 62% was normal, 23% was scar, and 15% was mismatch. Model predicted change
in EF of 4%; observed change was from 23% to 28%  5%.
Table 1. Patient Characteristics
Age (yrs) 62  9
Ejection fraction (%) 26  7
Men 62 (89%)
LMCA and/or three-vessel disease 49 (70%)
Hypertension 32 (46%)
Diabetes mellitus 25 (36%)
Previous CABG 6 (9%)
Dyspnea: NYHA class III–IV 51 (73%)
Angina: CCS class III–IV 35 (50%)
Quality of life questionnaire score (MLHF) 48  23
6-min walk test (m) 347  128
Time to revascularization (6 weeks) 50 (71%)
CABG  coronary artery bypass graft; CCS  Canadian Cardiovascular Society;
LMCA  left main coronary artery; MLHF  Minnesota Living with Heart Failure;
NYHA  New York Heart Association.
Table 2. Independent Predictors of Change in LV Function
Parameter
Coefficient
Value Beta SE p Value
Scar score (%LV) 0.451 0.097 0.001
Mismatch score (%LV) 0.319 0.177 0.085
Tracer 0.384 3.164 0.043
Tracer/mismatch interaction* 0.500 0.215 0.021
Time to OR (6 weeks) 0.286 1.969 0.008
Diabetes 0.237 1.878 0.029
Age 0.185 0.101 0.088
Previous CABG 0.110 3.164 0.295
*Reflects the contribution of the interaction term.
CABG  coronary artery bypass graft; LV  left ventricle; OR  revasculariza-
tion; SE  standard error.
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absolute change in EF while holding all other variables in
the model constant. For this analysis mean values were used
for continuous variables and modal values were used for
categorical variables (tracer  1, PET). The mean absolute
change in EF was 4.3  1.68%. A 10-point incremental
increase in the extent of scar would reduce the change in EF
by 3.38% to 0.94 2.16%. A 10-point increase in mismatch
using PET perfusion would increase the change in EF by
1.99% to 6.31  2.37%. The complete model explained
36.4% of the variance in EF. The observed versus the fitted
absolute changes in EF calculated from the multiple linear
regression are shown in Figure 2 (r  0.60; p  0.0003).
Extent of scar and LV function recovery. To illustrate the
relationship between scar score and change in EF, scar
scores were divided into tertiles: (I, small: 0% to 16%; II,
moderate: 16% to 27.5%; III, large: 27.5% to 47%). The
respective changes in EFs were 9.0 1.9%, 3.7 1.6%, and
1.3  1.5% (mean  SD). There was a statistically
significant difference in the absolute change of EF between
patients with small scar score (0% to 16% of LV) compared
with large scar score (27.5% to 47% of LV) (overall p 
0.006 by analysis of variance; p  0.002 for tertile I [small]
vs. III [large] by t test) (Fig. 3).
DISCUSSION
This prospective study demonstrates that in patients with
severe CAD and LV dysfunction, the amount of scar is an
important predictor of the extent of recovery after surgery.
The semiquantitative PET imaging methods allow objective
evaluation of viability. The PET parameters combined with
clinical parameters can be used to estimate the degree of LV
function recovery. To our knowledge, this is the largest such
study to integrate the clinical, demographic, and imaging
information into a prediction model for LV function recov-
ery post-revascularization.
Scar, mismatch, and LV function recovery. In the current
study, quantification of the amount of scar was an indepen-
dent predictor of improvement in LV function following
revascularization in patients with severe LV dysfunction.
Previous studies have focused on the importance of mis-
match (or hibernating myocardium) in predicting recovery
of function and improved outcome (2,4,5,7,10,14,18). The
current study indicates that scar should also be considered
and that PET parameters should be considered in the
clinical context.
Recent data from Pagano et al. and reports from Bax et al.
suggest that the number of viable dysfunctional segments
and the amount of mismatch are important for predicting
symptom and LV function recovery (19,49,50). In the study
by Pagano et al. (19) the number of viable segments, defined
by the rate of myocardial glucose utilization, was associated
with the change in EF (r  0.65). Unlike many previous
studies, Pagano et al. (19) defined viability independent of
perfusion. The current study showed similar results in that
the degree of scar (the corollary of the Pagano et al. (19)
glucose utilization) was a significant independent predictor
of LV function recovery. However, it also showed that a
prediction model that includes PET parameters (scar and
Figure 1 continued. (C) Small basal inferior scar is noted: 89% was
normal, 9% was scar, and 2% was mismatch. Model predicted change in EF
was 15%; observed change was from 23% to 37%  14%.
Table 3. Fitted Absolute and Incremental Changes in EF
Variable Change
Fitted Absolute
Change in EF 95% CI
Incremental Change
in EF*
Mean change (theoretical patient)* 4.32 (0.97, 7.68)
10 points increase in scar score 0.94 (3.39, 5.26) 3.38
10 points increase in mismatch score 6.31 (1.58, 11.05) 1.99
10 years increase in age 6.08 (1.70, 10.45) 1.76
Presence of diabetes mellitus 8.53 (4.33, 12.73) 4.21
*The fitted absolute change in ejection fraction (EF) in a patient (with mean values for each of the continuous variables in the
model, and assuming modal values for categorical variables with the tracer variable  1) is 4.32. The Table expresses the fitted
absolute change and incremental change in EF when an individual parameter is changed in this theoretical patient.
CI  confidence interval.
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mismatch) and clinical parameters can be used to estimate
the degree of recovery of LV function following revascular-
ization.
Others have also recently focused on the extent of scar. In
a cohort study, Haas et al. (20) used 50% FDG uptake as
cutoff for viability and defined an extent of scar 40% as
unlikely to recover with revascularization. Using FDG PET
to risk stratify with these cutoffs yielded improved postop-
erative and long-term outcomes compared to an approach
that did not utilize FDG PET (20). Further evidence on the
importance of the total extent of viability comes from
subsequent studies by Haas et al. (51,52). These data
indicate that dysfunctional regions with normal perfusion
(repetitively stunned myocardium) are more common than
mismatch (70% vs. 24% of dysfunctional segments). In
addition such “normal perfusion zones” have less associated
tissue injury and are more likely to demonstrate complete
recovery than mismatch segments (31% vs. 18%, respec-
tively) (51,52).
Retrospective studies evaluating FDG PET and long-
term patient outcome (2,5–7,12,35) suggest that FDG PET
potentially identifies high-risk patients that may benefit
from revascularization. Other studies have shown that FDG
PET is helpful in decision making for revascularization
(22–24), but it is difficult, without prospective randomized
controlled trials, to know whether therapy decisions are
indeed appropriate and impact on outcome. One random-
ized controlled trial has compared FDG PET guided
therapy to Tc-99m-sestamibi guided therapy (53). Al-
though there were minor trends, this study showed no
significant difference in outcome. However, the study fo-
cused on a lower risk group of patients (with mostly
moderate LV dysfunction), used only FDG mismatch to
define viability in hypoperfused segments, and was too small
to detect important differences (54). One of the aims of the
current study was the identification of a prediction model
that incorporates PET and clinical parameters and could be
applied in a prospective randomized controlled trial of
patients with severe LV dysfunction—the patient popula-
tion who will most likely benefit from viability detection.
Utility of the prediction model. In this study, several
clinical parameters had impact on LV function recovery.
The presence of higher risk parameters, including diabetes,
age, and previous revascularization, increased the degree of
recovery. At first glance, this may appear paradoxical.
However, other studies (55) have shown that the patients at
greatest risk are often those who gain the most benefit from
treatment. It is possible that older patients and those with
previous bypass have better developed collateral flow, which
could facilitate recovery. Alternatively, a selection bias may
have occurred whereby subjective criteria for revasculariza-
tion decisions are stricter with the higher risk patients. In
the case of diabetes, it may also indicate that the level of
viable myocardium is greater than apparent on imaging
because patients with diabetes tend to be more difficult to
image (56–60). Examples of applying the model to three
patients in the current study who had small, moderate, and
large scar areas are shown in Figure 1.
Study limitations. Some limitations of this approach are
worth considering. These primarily relate to the patient
population in this study, which included patients who were
predominantly men, predominately between 53 and 71 years
of age (1 standard deviation from the mean), had multivessel
disease, and had bypassable vessels. The generalizability of
the prediction model to a wider patient population is being
tested in a large randomized controlled trial (PET and
Recovery following Revascularization–Phase 2 [PARR-2]).
The current study was intended as a pilot study to
establish the prediction model for subsequent trials. The
sample size was larger than many PET studies evaluating
recovery of function. However, the sample size limited the
parameters that could be included in the prediction model.
Figure 2. Prediction model: observed vs. fitted change in absolute ejection
fraction. Correlation coefficient: r  0.60; p  0.0003.
Figure 3. Absolute change in ejection fraction (EF) versus scar scores:
small (0% to 16% of left ventricle [LV]), moderate (16% to 27.5% of LV),
and large (27.5% to 47% of LV); * p  0.002, small versus large scar score.
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Thus, some potentially important parameters, such as
stress-induced ischemia and ventricular volumes, were not
included. The number of parameters used simplifies the
model for research and clinical use but also means that
prediction rule for a given patient must be taken in the
context of clinical judgment and image interpretation. The
impact of some of these variables on the model will be tested
in the larger ongoing randomized control trial.
The use of both PET and SPECT perfusion agents in the
current study represents the clinical reality, as many insti-
tutions do not have easy access to PET perfusion agents.
This may account for the lack of significance of the
independent mismatch term. To account for potential
differences in mismatch due to the type of perfusion tracer
(PET or SPECT), an interaction variable (tracer variable)
was used in the model. When PET perfusion was used, the
overall effect of mismatch was for a predicted increase in EF.
When SPECT perfusion was used, the mismatch effect was
not significant and the confidence limits of the point
estimate overlap 0. Thus, interpretation of the effect of
mismatch with SPECT perfusion must be done cautiously.
This limitation of the model likely reflects the small sample
size. Ongoing clinical trials will allow evaluation of each
PET variable with greater accuracy.
Although improvement in LV function has been noted at
three months of follow-up in many previous studies, recent
data suggest that more recovery may be observed with
longer follow-up time (51,52,61). The impact of follow-up
time on the model could not be addressed in the current
study but will be considered in the larger ongoing random-
ized control trial that will follow up patients up to two years.
It could be argued the angiographic data should be
included in the model. Clearly this is an important param-
eter in decision making. However, patients in this study did
have suitable anatomy for revascularization. If they did not,
they were not generally considered for revascularization and
the model would not be applicable. Second, many patients
referred for PET (about 50% in our institution) have not
had a recent angiogram. Therefore, coronary anatomy data
would not always be available to incorporate into the model.
The prospective randomized controlled trial (PARR-2)
includes patients who have as well as those who have not
had recent angiography before the PET study: so the model
can be validated in this patient population.
CONCLUSIONS
In patients with severe CAD and LV dysfunction, quanti-
fication of the amount of scar with FDG PET and perfusion
imaging is important in predicting the extent of recovery of
LV function after revascularization. The percent of the LV
with scar was the most important predictor. A prediction
model that combines PET and clinical parameters can be
used to predict the degree of recovery of LV function.
These data set the framework for larger scale future
studies evaluating the application of FDG PET. The
prediction model is now being applied in a large multicenter
randomized controlled trial (PARR-2) to determine the
clinical outcome and cost-effectiveness of therapy guided by
FDG PET.
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APPENDIX
Participating Sites (Investigators and Research Coordi-
nators): University of Ottawa Heart Institute (R. Bean-
lands, T. Ruddy, R. deKemp, P. Hendry, R. Masters,
S. Smith, R. A. Davies, M. Labinaz, D. S. Beanlands,
B. Aubrey, L. Garrard); E. S. Garnett Memorial PET
Centre, Department of Radiology, McMaster University
and Department of Nuclear Medicine, Hamilton Health
Sciences (E. Fallen, C. Nahmias, G. Firnau, A. Lamy,
G. Woodcock, M. Thompson); Hospitals of the University
of Toronto Health Sciences Network (Toronto Hospital
Western and General Divisions) (R. Burns, R. M. Iwan-
ochko, L. Mickelborough, P. P. Liu); St. Michael’s Hospi-
tal (M. Freeman, D. Latter); London Health Sciences
Centre (W. Kostuk).
Core labs: PET and perfusion imaging: University of
Ottawa Heart Institute (R. deKemp, M. Aung); RA (R.
Burns, R. M. Iwanochko, R. Burke).
Statistical analysis: CORE Group, Department of Epide-
miology and Community Medicine, University of Ottawa
(G. Nichol, J. Blackburn).
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